Lotte M G Steuten

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5118644/publications.pdf

Version: 2024-02-01

68 papers	2,320 citations	218677 26 h-index	223800 46 g-index
70 all docs	70 docs citations	70 times ranked	3559 citing authors

#	Article	IF	Citations
1	Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS. JAMA - Journal of the American Medical Association, 2018, 320, 1872.	7.4	195
2	COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 84-91.	2.3	145
3	Early Assessment of Medical Technologies to Inform Product Development and Market Access. Applied Health Economics and Health Policy, 2011, 9, 331-347.	2.1	136
4	Delivering precision oncology to patients with cancer. Nature Medicine, 2022, 28, 658-665.	30.7	125
5	A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice. Pharmacoeconomics, 2013, 31, 25-48.	3.3	110
6	Effectiveness of Multidimensional Cancer Survivor Rehabilitation and Cost-Effectiveness of Cancer Rehabilitation in General: A Systematic Review. Oncologist, 2012, 17, 1581-1593.	3.7	109
7	Value of Information Analysis for Research Decisionsâ€"An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, 2020, 23, 139-150.	0.3	105
8	Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life. Radiotherapy and Oncology, 2014, 112, 77-82.	0.6	85
9	Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach. International Journal of Technology Assessment in Health Care, 2008, 24, 459-464.	0.5	77
10	Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, 2020, 23, 277-286.	0.3	75
11	Quality of integrated chronic care measured by patient survey: identification, selection and application of most appropriate instruments. Health Expectations, 2009, 12, 417-429.	2.6	74
12	Metaâ€analysis of the effectiveness of chronic care management for diabetes: investigating heterogeneity in outcomes. Journal of Evaluation in Clinical Practice, 2013, 19, 753-762.	1.8	73
13	The Effectiveness of Chronic Care Management for Heart Failure: Meta€Regression Analyses to Explain the Heterogeneity in Outcomes. Health Services Research, 2012, 47, 1926-1959.	2.0	71
14	Evaluation of a regional disease management programme for patients with asthma or chronic obstructive pulmonary disease. International Journal for Quality in Health Care, 2006, 18, 429-436.	1.8	48
15	Economic evaluation of nurse practitioners versus GPs in treating common conditions. British Journal of General Practice, 2010, 60, e28-e35.	1.4	48
16	A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. Journal of Medical Economics, 2015, 18, 944-953.	2.1	47
17	Costâ€"effectiveness analysis of telemonitoring versus usual care in patients with heart failure: The TEHAFâ€"study. Journal of Telemedicine and Telecare, 2013, 19, 242-248.	2.7	43
18	Chronic care management for patients with COPD: a critical review of available evidence. Journal of Evaluation in Clinical Practice, 2013, 19, 734-752.	1.8	40

#	Article	IF	Citations
19	A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. BMC Cancer, 2011, 11, 475.	2.6	39
20	Integrating Health Economics Into the Product Development Cycle. Medical Decision Making, 2011, 31, 596-610.	2.4	37
21	Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. Journal of Cancer Survivorship, 2015, 9, 126-135.	2.9	33
22	Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. OMICS A Journal of Integrative Biology, 2019, 23, 508-515.	2.0	33
23	Cost-utility of a disease management program for patients with asthma. International Journal of Technology Assessment in Health Care, 2007, 23, 184-191.	0.5	32
24	Uncertainty of Physicians and Patients in Medical Decision Making. Biology of Blood and Marrow Transplantation, 2017, 23, 865-869.	2.0	30
25	Are we measuring what matters in health technology assessment of disease management? Systematic literature review. International Journal of Technology Assessment in Health Care, 2006, 22, 47-57.	0.5	28
26	A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers. Applied Health Economics and Health Policy, 2016, 14, 51-65.	2.1	28
27	Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. Applied Health Economics and Health Policy, 2022, 20, 105-117.	2.1	25
28	The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS ONE, 2019, 14, e0214222.	2.5	23
29	Cost-Utility of Metal-on-Metal Hip Resurfacing Compared to Conventional Total Hip Replacement in Young Active Patients with Osteoarthritis. Value in Health, 2013, 16, 942-952.	0.3	22
30	Development of a web-based tool for the assessment of health and economic outcomes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). BMC Medical Informatics and Decision Making, 2015, 15, S4.	3.0	20
31	Improving early cycle economic evaluation of diagnostic technologies. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 491-498.	1.4	19
32	Long-term costâ€“effectiveness of Oncotype DX ^{Â®} versus current clinical practice from a Dutch cost perspective. Journal of Comparative Effectiveness Research, 2015, 4, 433-445.	1.4	19
33	Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?. Pediatric Radiology, 2018, 48, 1472-1484.	2.0	19
34	Commercial viability of medical devices using Headroom and return on investment calculation. Technological Forecasting and Social Change, 2016, 112, 338-346.	11.6	18
35	Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. BMC Cancer, 2018, 18, 895.	2.6	17
36	Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development. Applied Health Economics and Health Policy, 2014, 12, 327-334.	2.1	16

#	Article	IF	Citations
37	Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries. BMC Cancer, 2015, 15, 899.	2.6	15
38	Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thrombosis Research, 2019, 180, 37-42.	1.7	15
39	Analysing uncertainty around costs of innovative medical technologies: The case of fibrin sealant (QUIXILA®) for total knee replacement. Health Policy, 2009, 89, 46-57.	3.0	14
40	Cost-effectiveness of heat and moisture exchangers compared to usual care for pulmonary rehabilitation after total laryngectomy in Poland. European Archives of Oto-Rhino-Laryngology, 2015, 272, 2381-2388.	1.6	14
41	An Appeal to the Global Health Community for a Tripartite Innovation: An â€œEssential Diagnostics List,â€• â€œHealth in All Policies,â€•and â€œSee-Through 21st Century Science and Ethicsâ€• OMICS A Journal of Integrative Biology, 2015, 19, 435-442.	2.0	14
42	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. Cancer Treatment Reviews, 2017, 52, 117-127.	7.7	13
43	Predicting the health economic performance of new nonâ€fusion surgery in adolescent idiopathic scoliosis. Journal of Orthopaedic Research, 2012, 30, 1453-1458.	2.3	12
44	A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. European Archives of Oto-Rhino-Laryngology, 2016, 273, 709-718.	1.6	12
45	Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise. Value in Health, 2017, 20, 1336-1344.	0.3	12
46	Realising the broader value of vaccines in the UK. Vaccine: X, 2021, 8, 100096.	2.1	12
47	Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1133-1139.	0.9	11
48	Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy. Breast, 2015, 24, 397-405.	2.2	10
49	Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis. Value in Health, 2016, 19, 419-430.	0.3	10
50	Health technology assessment of asthma disease management programs. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 242-248.	2.3	9
51	Transferability of economic evaluations of medical technologies: a new technology for orthopedic surgery. Expert Review of Medical Devices, 2008, 5, 329-336.	2.8	9
52	A Call for Pharmacogenovigilance and Rapid Falsification in the Age of Big Data: Why not First Road Test Your Biomarker?. OMICS A Journal of Integrative Biology, 2014, 18, 663-665.	2.0	9
53	Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics. JAMA Oncology, 2015, 1, 571.	7.1	9
54	Procalcitonin Biomarker Algorithm Reduces Antibiotic Prescriptions, Duration of Therapy, and Costs in Chronic Obstructive Pulmonary Disease: A Comparison in the Netherlands, Germany, and the United Kingdom. OMICS A Journal of Integrative Biology, 2017, 21, 232-243.	2.0	8

#	Article	IF	Citations
55	Is it economically viable to employ the nurse practitioner in general practice?. Journal of Clinical Nursing, 2011, 20, 518-529.	3.0	7
56	Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine. OMICS A Journal of Integrative Biology, 2016, 20, 30-35.	2.0	7
57	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. Applied Health Economics and Health Policy, 2019, 17, 733-740.	2.1	7
58	Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients. PLoS ONE, 2016, 11, e0154386.	2.5	5
59	Comparative cost-effectiveness of focal and total salvage 125 I brachytherapy for recurrent prostate cancer after primary radiotherapy. Journal of Contemporary Brachytherapy, 2016, 6, 484-491.	0.9	4
60	Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking. OMICS A Journal of Integrative Biology, 2016, 20, 493-495.	2.0	4
61	Health Economic Evaluation of a Strict Glucose Control Guideline Implemented Using Point-of-Care Testing in Three Intensive Care Units in The Netherlands. Applied Health Economics and Health Policy, 2015, 13, 399-407.	2.1	3
62	Multi-Dimensional Impact of the Publicâ€“Private Center for Translational Molecular Medicine (CTMM) in the Netherlands: Understanding New 21st Century Institutional Designs to Support Innovation-in-Society. OMICS A Journal of Integrative Biology, 2016, 20, 265-273.	2.0	3
63	Is Procalcitonin Biomarker-Guided Antibiotic Therapy a Cost-Effective Approach to Reduce Antibiotic Resistant and Clostridium difficile Infections in Hospitalized Patients?. OMICS A Journal of Integrative Biology, 2018, 22, 616-625.	2.0	3
64	Economic value of procalcitonin guidance. Lancet Infectious Diseases, The, 2016, 16, 1000.	9.1	2
65	Personalized Dentistry Meets OMICS and â€œOne Healthâ€: From Cinderella of Healthcare to Mainstream?. OMICS A Journal of Integrative Biology, 2015, 19, 145-146.	2.0	1
66	A SYSTEMATIC APPROACH FOR ASSESSING, IN THE ABSENCE OF FULL EVIDENCE, WHETHER MULTICOMPONENT INTERVENTIONS CAN BE MORE COST-EFFECTIVE THAN SINGLE COMPONENT INTERVENTIONS. International Journal of Technology Assessment in Health Care, 2017, 33, 444-453.	0.5	1
67	How to Move From Belief to Proof? Articulating the Value of Chronic Disease and Care Management Programs for Adults With Asthma. Respiratory Care, 2009, 54, 844-846.	1.6	1
68	To Genotype or Phenotype for Drug and Food Safety? Exiting the Technology Echo Chambers. OMICS A Journal of Integrative Biology, 2018, 22, 525-527.	2.0	0